2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.16 Neoadjuvant Chemoimmunotherapy in the Treatment of Stage III Non-Small Cell Lung Cancer: A Single-Center Initial Results.

EP.08D.16 Neoadjuvant Chemoimmunotherapy in the Treatment of Stage III Non-Small Cell Lung Cancer: A Single-Center Initial Results.

Back to course

Pdf Summary

This study discusses the use of neoadjuvant chemoimmunotherapy for patients with stage III resectable non-small cell lung cancer (NSCLC) at the Loginov Moscow Medical Scientific Center, assessing its efficacy and safety. From 2023 to 2024, 22 patients who did not have activating mutations underwent three cycles of chemoimmunotherapy before surgery. The response to treatment was significant, with a 90.9% overall response rate; 18.2% achieved complete response (CR), 72.7% partial response (PR), and 9.1% showed stable disease (SD).<br /><br />All patients proceeded to surgical intervention after initial treatment. Surgical procedures varied but included minimally invasive methods in 18.2% of cases, and techniques such as lobectomy, sleeve lobectomy, and pneumonectomy were performed based on individual cases. A total of 36.4% of patients achieved complete pathological response (CR), and 59.1% showed major response (MR), with only one patient showing no response.<br /><br />Importantly, there were no significant postoperative complications, and there were no mortalities within 30 or 90 days after surgery. The study concluded that neoadjuvant chemoimmunotherapy followed by surgery is a safe and effective treatment for stage III NSCLC, leading to substantial pathological responses and allowing for the potential reduction in surgical volume.<br /><br />However, it is noted that the study has limitations including the absence of PD-L1 scoring data and a short follow-up period. Further research is suggested to validate these findings and explore long-term outcomes. Overall, the initial results support the feasibility and safety of this combined treatment approach in managing locally advanced stage III NSCLC.

Asset Subtitle

Parvin Akhmedov

Meta Tag

Speaker Parvin Akhmedov

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

neoadjuvant chemoimmunotherapy

stage III NSCLC

Loginov Moscow Medical Scientific Center

efficacy and safety

surgical intervention

pathological response

postoperative complications

PD-L1 scoring

treatment feasibility

long-term outcomes